top of page

Health Canada Approved: First RSV Vaccine for 60+

As we know well from the COVID-19 pandemic, older adults are especially vulnerable to respiratory infections and the life-threatening consequences. Now, Health Canada has approved GSK’s Arexvy, the first vaccine to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) for adults aged ≥60 years.

RSV is a common and highly contagious virus that can lead to pneumonia, hospitalization and even death for some people, especially older adults with weakened immune systems. In the pivotal AReSVi-006 phase III trial in adults aged ≥60 years, Arexvy efficacy against RSV-related lower respiratory tract disease was 82.6% overall and 94.1% in patients with comorbidities.

Arexvy is delivered intramuscularly as a single dose with further guidance from the National Advisory Committee on Immunization (NACI) expected next year. In the meantime, only limited quantities of Arexvy are expected to be available for the fast-approaching Fall respiratory virus season. Still, its approval offers hope for piece of mind for older Canadians.


Recent Posts
bottom of page